Skylark Bio

Skylark Bio is a private, pre-clinical stage biotech firm developing next-generation gene therapies. Its core focus is on creating novel viral vector and delivery systems designed to improve the safety, efficacy, and targeting of genetic medicines. Operating from the key biotech hub of Cambridge, the company is positioned to tackle challenging genetic disorders but remains in the early, high-risk stages of research and development with no disclosed pipeline or clinical programs.

Novel viral vector and delivery technologies for gene therapy, likely involving engineered capsids or vector systems designed for improved safety, targeting, and efficacy.

Skylark Bio competes in a crowded and rapidly advancing field of gene therapy delivery, facing competition from both large biopharma companies (e.g., Roche, Novartis, Pfizer) and numerous nimble biotechs (e.g., Dyno Therapeutics, Ring Therapeutics, 4D Molecular Therapeutics) also engineering next-generation viral vectors and delivery platforms.